Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

Organon and Co555 enrolled

Overview

This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.

Study Type

OBSERVATIONAL

Enrollment

555

Conditions

Coronary Heart Disease Hypercholesterolemia Hyperlipidemia

Interventions

StatinDRUG

Statin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * willingness to participate in the study * 18 years of age or more * clinically established cardiovascular disease to be considered as patients in secondary prevention * prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed Exclusion Criteria: * None

Outcomes

Primary Outcomes

percentage of patients reaching target LDL levels

Time frame: 6-8 weeks after first visit and 28-32 weeks after first visit

Secondary Outcomes

measure patient compliance to treatment as assessed by counting returned tablets

Time frame: 6-8 weeks after first visit and 28-32 weeks after first visit